MedPath
Found 2 clinical trials|View Analysis
Sort by:

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1
Recruiting
Conditions
MTAP-null Non-Small-Cell Lung Cancer
MTAP-null Solid Tumors
Interventions
Drug: AMG 193
Drug: IDE397
First Posted Date
2023-08-03
Last Posted Date
2025-01-03
Lead Sponsor
Amgen
Target Recruit Count
184
Registration Number
NCT05975073
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Sarah Cannon Research Institute, Denver, Colorado, United States

🇺🇸

Community Health Network MD Anderson Cancer Center - North, Indianapolis, Indiana, United States

and more 24 locations

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2021-03-12
Last Posted Date
2024-11-18
Lead Sponsor
IDEAYA Biosciences
Target Recruit Count
180
Registration Number
NCT04794699
Locations
🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath